GlassScriptPhysician profile
Andrew S Bagg
NPI 1962588053
$113,007.92
in general payments reported to CMS, 2019-2025
38 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $9,404 · 2021: $23K · 2022: $12K · 2023: $10K · 2024: $24K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Food and Beverage: $12K · Consulting Fee: $4,447 · Travel and Lodging: $2,782 · Honoraria: $350 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,045.00 |
| Food and Beverage | $12,247.16 |
| Consulting Fee | $4,447.14 |
| Travel and Lodging | $2,782.13 |
| Honoraria | $350.00 |
| Education | $182.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $51,379.57 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $26,799.58 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $10,871.94 | 2019-2025 | Dupixent |
| Csl Behring | $7,318.73 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $3,141.81 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $2,875.80 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $2,504.30 | 2021-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $1,760.20 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Biocryst Pharmaceuticals, INC. | $1,125.00 | 2020 | |
| Genzyme Corporation | $1,063.47 | 2019-2025 | |
| Pfizer INC. | $624.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $513.01 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $461.23 | 2020-2024 | |
| Optinose US, INC. | $441.54 | 2021-2025 | |
| Genentech USA, INC. | $321.40 | 2019-2025 | Xolair |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $202.91 | 2019-2025 | Xembify |
| Amgen INC. | $198.96 | 2022-2025 | Tezspire, Otezla |
| Alk-Abello, INC | $177.08 | 2019-2022 | |
| Blueprint Medicines Corporation | $162.95 | 2023-2025 | Ayvakit |
| Octapharma USA, INC. | $121.76 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.57 | 2020-2023 | Spiriva Respimat |
| Covis Pharma Gmbh | $98.38 | 2021-2022 | |
| Kaleo, INC. | $95.36 | 2019-2023 | Auvi-Q |
| Abbvie INC. | $94.11 | 2020-2023 | Rinvoq |
| Shire North American Group INC | $83.19 | 2019 | |
| Ionis Pharmaceuticals, INC. | $77.59 | 2025 | Dawnzera |
| Gc Biopharma USA, INC. | $64.89 | 2024-2025 | Alyglo, Alyglo |
| Teva Pharmaceuticals USA, INC. | $56.20 | 2020-2022 | |
| Galderma Laboratories, L.P. | $51.61 | 2024 | Aklief |
| Bio Products Laboratory USA, INC. | $42.43 | 2021-2023 | Coagadex, Gammaplex |
| Adma Biomanufacturing LLC | $29.64 | 2023 | |
| Organon LLC | $28.62 | 2025 | |
| Leo Pharma INC. | $27.30 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.48 | 2019 | |
| Merck Sharp & Dohme LLC | $17.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Hikma Pharmaceuticals USA | $13.71 | 2024 | Ryaltris |
| Phadia US INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bagg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.